GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports positive interim data from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer. The single-arm study met its primary objective, showing a meaningful, sustained clinical complete response at 12 months (cCR12), with participants having no detectable signs of cancer one year or more after treatment.
The results suggest that dostarlimab monotherapy could eliminate or delay the need for chemotherapy, radiation and surgery for some patients in this population, where current standard treatments often cause long-term quality-of-life issues. AZUR-1 enrolled 154 participants, each receiving nine cycles of 500 mg intravenous dostarlimab every three weeks over six months. The safety profile in this setting was consistent with the established, manageable profile across solid tumours.
Dostarlimab has Breakthrough Therapy and Fast Track designations from the FDA in this indication. GSK plans to share AZUR-1 interim data with global regulators, seeking review, including accelerated pathways, and will present detailed results at a future scientific congress. Jemperli is not currently approved for rectal cancer.
GSK plc reports that its licensor Hansoh Pharmaceutical Group achieved positive pivotal phase III results for risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer in a China patient population. The ARTEMIS-008 study met its primary endpoint of overall survival, showing statistically significant and clinically meaningful benefit versus topotecan, with consistent improvements in key secondary endpoints such as progression-free survival and a safety profile in line with prior data.
These data will support Hansoh Pharma's regulatory submission in China. GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan and is running a broad programme across lung, prostate and other solid tumours, including the global phase III EMBOLD SCLC-301 trial in relapsed extensive-stage small-cell lung cancer, where pivotal data are expected next year. The company highlights this as the first positive phase III overall survival result for a B7-H3-targeted antibody-drug conjugate in any tumour type.
GSK plc reported that senior executive Maya Martinez-Davis acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account. The transaction involved 8.955 notional ADS at a price of $53.3200 per ADS on 7 July 2026, executed on the New York Stock Exchange.
GSK plc has appointed Roy Jakobs to its Board as an independent Non-Executive Director, effective 13 July 2026. He is currently Chief Executive Officer of Royal Philips, a global health technology company with 2025 sales of 17.8 billion EUR and 65,000 employees.
GSK’s Board determined that Jakobs meets independence criteria under the UK Corporate Governance Code. He will receive the standard annual Non-Executive Director fee of £122,258 and is required to build a holding of GSK shares equal to two times this fee, in line with the shareholder-approved Non-Executive Director remuneration policy.
GSK plc reported its total voting rights and share capital as of 30 June 2026. The company had 4,316,276,428 issued ordinary shares of 31¼ pence each, including 270,881,064 shares held in treasury.
This leaves 4,045,395,364 voting rights, which shareholders can use as the reference figure when deciding whether they must disclose holdings or changes under the UK Financial Conduct Authority’s transparency rules.
GSK plc reports that it has repurchased ordinary shares under its existing buyback programme, using Citigroup Global Markets Limited as broker, and has now completed the buyback of up to £2 billion announced on 24 February 2025.
Between 22 and 26 June 2026, GSK bought 1,054,653 ordinary shares of 31¼ pence each at volume-weighted average prices between 1,919.89 and 1,967.46 GBp per share. Since 24 February 2025, it has purchased 123,939,156 ordinary shares for aggregate consideration of just under £2 billion. After these purchases, GSK holds 270,881,064 shares in treasury and has 4,045,395,364 ordinary shares in issue, so total voting rights are 4,045,395,364 and 6.70 per cent of voting rights are now attributable to treasury shares.
GSK plc reports a regulatory notification of major holdings after a shareholder’s stake fell below a key threshold. The holder’s total voting rights decreased from 5.010000% to 4.960000%, representing 201,065,668 voting rights in GSK.
The position is split between ordinary shares and American Depositary Receipts (ADRs). Ordinary shares carry 88,816,040 indirect voting rights, equal to 2.190000% of voting rights, while ADRs carry 112,249,628 indirect voting rights, equal to 2.770000% of voting rights. No additional voting rights are held through financial instruments.
GSK plc reports a change in a major shareholding, as a notification under the TR-1 regime shows the holder’s total voting interest reaching 5.010000% of voting rights in the company. This corresponds to 203,320,168 voting rights in total, up from a previously reported position of 4.930000%.
The interest is held entirely through shares rather than derivative or other financial instruments. It includes voting rights linked to ordinary shares with ISIN GB00BN7SWP63 and to ADRs with ISIN US37733W2044. No additional voting rights are reported through financial instruments in this notification.
GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through a company savings plan. The transaction involved 9.4103 ADS at a price of $50.7400 per ADS on the New York Stock Exchange on 2026-06-22, within her GSK Executive Supplemental Savings Plan account.
GSK plc has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. The offer is being made through Harmony Row Acquisition Co., a wholly owned subsidiary of GlaxoSmithKline LLC, under an Agreement and Plan of Merger dated June 9, 2026.
After the tender offer is completed and conditions are met, Harmony Row Acquisition Co. will merge into Nuvalent under Section 251(h) of the Delaware General Corporation Law, making Nuvalent a wholly owned subsidiary of GSK LLC. Nuvalent’s board has recommended that stockholders accept the offer. The offer and withdrawal rights are scheduled to expire at one minute after 11:59 p.m. Eastern Time on July 14, 2026, unless extended or terminated.